Online inquiry

IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12538MR)

This product GTTS-WQ12538MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets PDCD1 gene. The antibody can be applied in Hepatocellular carcinoma (HCC) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_005018.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 5133
UniProt ID Q15116
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PDCD1, NPVPDR001(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12538MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ358MR IVTScrip™ mRNA-Anti-ALB&IL6R, 20A11-9mer-ALB11(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA 20A11-9mer-ALB11
GTTS-WQ9656MR IVTScrip™ mRNA-Anti-CD3E&TNFRSF17, JNJ-64007957(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA JNJ-64007957
GTTS-WQ11768MR IVTScrip™ mRNA-Anti-CTLA4, MK-1308(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MK-1308
GTTS-WQ2272MR IVTScrip™ mRNA-Anti-C5, ALXN1007(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALXN1007
GTTS-WQ7413MR IVTScrip™ mRNA-Anti-EGFR, GA201(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA GA201
GTTS-WQ8499MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ3199MR IVTScrip™ mRNA-Anti-ANPEP, ARENEGYR(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA ARENEGYR
GTTS-WQ13785MR IVTScrip™ mRNA-Anti-MSTN, REGN-1033(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-1033
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW